Kepler Capital Keeps Their Sell Rating on ElringKlinger (0MG5)
Kepler Capital analyst Michael Raab maintained a Sell rating on ElringKlinger (0MG5 – Research Report) on May 8 and set a price target of €3.00. The company's shares closed last Thursday at €4.71.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Raab is a 5-star analyst with an average return of 13.6% and a 57.57% success rate.
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for ElringKlinger with a €3.50 average price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Oppenheimer Remains a Buy on Nurix Therapeutics (NRIX)
Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Nurix Therapeutics (NRIX – Research Report) yesterday and set a price target of $32.00. The company's shares closed last Friday at $11.93. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Biegler is an analyst with an average return of -12.1% and a 31.68% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Regeneron, and Nurix Therapeutics. In addition to Oppenheimer, Nurix Therapeutics also received a Buy from Truist Financial's Srikripa Devarakonda in a report issued on June 13. However, on June 3, Leerink Partners reiterated a Hold rating on Nurix Therapeutics (NASDAQ: NRIX).
Business Insider
4 hours ago
- Business Insider
Honeywell open to acquiring more companies in Europe, Bloomberg says
Honeywell (HON) is open to acquiring more companies in Europe as it looks to increase its portfolio, Kate Duffy of Bloomberg reports. 'We're open across the board where those things fit,' Chief Commercial and Strategy Officer Ben Driggs said in an interview, according to Bloomberg. 'There is absolutely growth in defense that we want to take advantage of.' Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
4 hours ago
- Business Insider
Ord Minnett Remains a Buy on Regis Healthcare Ltd. (REG)
Ord Minnett analyst Tom Godfrey maintained a Buy rating on Regis Healthcare Ltd. (REG – Research Report) today and set a price target of A$8.25. The company's shares opened today at A$7.36. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Godfrey is a 3-star analyst with an average return of 7.9% and a 36.73% success rate. Godfrey covers the Healthcare sector, focusing on stocks such as Monash IVF Group Ltd, Sigma Healthcare Ltd, and EBOS Group Limited. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Regis Healthcare Ltd. with a A$8.93 average price target, representing a 21.33% upside. In a report released on June 5, Jefferies also maintained a Buy rating on the stock with a A$8.80 price target.
